Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses siRNA IP to Bio-Rad

NEW YORK (GenomeWeb News) — Alnylam Pharmaceuticals today said it has granted Bio-Rad non-exclusive rights to sell RNAi products based on certain of its IP.
 
The license falls under Alnylam’s Kreutzer-Limmer patent family, which covers the use of small interfering RNAs and “their use to mediate RNAi in mammalian cells,” the RNAi drug maker said.
 
Financial terms of the agreement were not released.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.